This inventor holds 17 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Aktiengesellschaft, Bayer Healthcare Aktiengesellschaft, Bayer Intellectual Property Gmbh. Active years: 2002-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Köln, DE (2002 - 2004)
- Mountain View, CA (US) (2006)
- Watertown, MA (US) (2014 - 2017)
- Menlo Park, CA (US) (2006 - 2019)
Company Filing History:
6 out of 12,269 
4 out of 77 
3 out of 721 
Years Active: 2002-2019
Areas of Expertise:
Title: **Innovator Spotlight: Rudy Schreiber**
Introduction
Rudy Schreiber is a notable inventor based in Watertown, Massachusetts, who has made significant contributions to the field of neuroscience through his innovative work. With a total of two patents to his name, Schreiber's inventions showcase his dedication to advancing medical treatments, particularly in the realm of neurological disorders.
Latest Patents
Schreiber's most recent patents focus on "Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors." These include the phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization. The compounds developed through his research aim to treat and prevent various neurological disorders by inhibiting the reuptake of endogenous monoamines such as dopamine, serotonin, and norepinephrine. Moreover, the invention provides formulations that incorporate these compounds, enhancing their potential for effective therapeutic applications.
Career Highlights
Throughout his career, Rudy Schreiber has been associated with Sunovion Pharmaceuticals Inc., a company widely recognized for its commitment to innovative therapies in mental health and neurological conditions. His work in developing novel compounds demonstrates an intersection of scientific research and practical application, contributing to advancements that may improve patient outcomes.
Collaborations
In his journey of innovation, Schreiber has collaborated with esteemed colleagues, including Liming Shao and Fengjiang Wang. These collaborations underline the importance of teamwork in research and development, paving the way for significant breakthroughs in pharmaceuticals.
Conclusion
Rudy Schreiber exemplifies the spirit of innovation through his dedicated work on monoamine reuptake inhibitors. His contributions, particularly in treating neurological disorders, highlight the vital role of inventors in advancing science and improving health outcomes. As he continues his work in the dynamic environment of Sunovion Pharmaceuticals Inc., the potential for further impactful inventions remains high.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile